insights_auto
Pse ƫshtƫ rritur AXGN 2,61%?
Zhytu mƫ thellƫchevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
50,02Ā US$
arrow_upward
+2,61%(+1,27) 1D
50,00Ā US$
arrow_downward
-0,04% (-0,020)bedtimeJashtƫ orarit
Mbyllur: 6 nĆ«n, 4:00:01āÆm.d., GMT-5 · USD
search
TĆ« gjitha simbolet
| Me simbole | Ćmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore pƫr AXGN...
Hap
48,55Ā US$
I lartƫ
50,29Ā US$
I ulƫt
48,14Ā US$
Kapitalizimi i tregut
2,99Ā mld
VĆ«llimi mesatar
1,79Ā mln
VĆ«llimi
1,67Ā mln
Maksimumi 52-javor
52,91Ā US$
Minimumi 52-javor
23,00Ā US$
Fitimet pƫr aksion
-0,68Ā US$
Beta
1,21
Aksionet nƫ qarkullim
59,73Ā mln
Numri i punonjƫsve
622
Hap
48,55Ā US$
I lartƫ
50,29Ā US$
I ulƫt
48,14Ā US$
Kapitalizimi i tregut
2,99Ā mld
VĆ«llimi mesatar
1,79Ā mln
VĆ«llimi
1,67Ā mln
Maksimumi 52-javor
52,91Ā US$
Minimumi 52-javor
23,00Ā US$
Fitimet pƫr aksion
-0,68Ā US$
Beta
1,21
Aksionet nƫ qarkullim
59,73Ā mln
Numri i punonjƫsve
622
Lajmet
Nga burimet nƫ ueb dhe partnerƫt e lajmeve
Yahoo! Finance Canada
·
1 ditƫ mƫ parƫ
Axogen, Inc. (AXGN) Seasonal Returns Chart - Yahoo Finance
Profili
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Rreth AxoGen, Inc Common Stock
Drejtori ekzekutiv-
Punonjƫsit622
Themeluar mƫ2002
SeliaAlachua, Florida, Shtetet e Bashkuara tƫ Amerikƫs
SektoriHealth Care
IndustriaMedical device
Uebsajtiaxogeninc.com